Elshenawi Yasmine, Hu Shuai, Hathroubi Skander
Department of Microbiology and Environmental Toxicology, University of California, Santa Cruz, CA 95064, USA.
Spartha Medical, CRBS 1 Rue Eugène Boeckel, 67000 Strasbourg, France.
Antibiotics (Basel). 2023 Jul 31;12(8):1260. doi: 10.3390/antibiotics12081260.
is a gastric pathogen that infects nearly half of the global population and is recognized as a group 1 carcinogen by the Word Health Organization. The global rise in antibiotic resistance has increased clinical challenges in treating infections. Biofilm growth has been proposed to contribute to colonization of the host stomach, treatment failures, and the eventual development of gastric diseases. Several components of have been identified to promote biofilm growth, and several of these may also facilitate antibiotic tolerance, including the extracellular matrix, outer membrane proteins, shifted morphology, modulated metabolism, efflux pumps, and virulence factors. Recent developments in therapeutic approaches targeting biofilm have shown that synthetic compounds, such as small molecule drugs and plant-derived compounds, are effective at eradicating biofilms. These combined topics highlight the necessity for biofilm-based research in , to improve current -targeted therapeutic approaches and alleviate relative public health burden. In this review we discuss recent discoveries that have decoded the life cycle of biofilms and current biofilm-targeted treatment strategies.
是一种胃部病原体，感染了全球近一半的人口，被世界卫生组织认定为1类致癌物。全球抗生素耐药性的上升增加了治疗感染的临床挑战。有人提出生物膜生长有助于在宿主胃部定植、治疗失败以及最终胃部疾病的发展。已确定的若干成分可促进生物膜生长，其中一些成分还可能促进抗生素耐受性，包括细胞外基质、外膜蛋白、形态改变、代谢调节、外排泵和毒力因子。针对生物膜的治疗方法的最新进展表明，合成化合物，如小分子药物和植物衍生化合物，在根除生物膜方面是有效的。这些综合主题凸显了在幽门螺杆菌中开展基于生物膜研究的必要性，以改进当前针对幽门螺杆菌的治疗方法并减轻相关的公共卫生负担。在这篇综述中，我们讨论了最近揭示幽门螺杆菌生物膜生命周期的发现以及当前针对生物膜的治疗策略。
